Starling Oncology, Inc. (STLNW) Return on equity 2020–2024
Starling Oncology, Inc. (STLNW) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-1801.7%FY2024 · since FY2020: -51.0% → -1801.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -1801.7% | -1656.0 pp |
| FY2023 | -145.7% | -145.8 pp |
| FY2022 | 0.1% | +10.6 pp |
| FY2021 | -10.5% | +40.5 pp |
| FY2020 | -51.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating marginSTLNW Operating cash flowSTLNW Free cash flowSTLNW Capital expendituresSTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →